How automated material handling systems are redefining the future of pharmaceutical manufacturing
The pharmaceutical industry is entering a period of growth that will challenge manufacturers' ability to get products out the door quickly, reliably and at lower risk. Add a shrinking pool of skilled labor and a wave of planned investment in capacity for peptides, biologics, sterile injectables, antibody-drug conjugates (ADCs) and other advanced modalities, and the strain on the industry becomes obvious.
The scale of what's coming is hard to overstate: analysts expect the global pharmaceutical market to top $2.6 trillion by 2030, and billions in new manufacturing investment have already moved toward flexible, digitalized facilities built for the next generation of medicines. That growth only sharpens the labor problem — roughly one in three biopharma executives already report critical talent shortages across therapeutic modalities and engineering disciplines. And it isn't just about scale. Modern facilities have to manage more complex material flows and tighter timelines while maintaining expectations for quality and operational resilience, all at once.
Defining automated material handling
This tension is the strategic opening that automated material handling systems are built to fill. It's worth being precise about what the term means: it describes a facility-wide transformation that reshapes material flow, architecture, digital infrastructure and workforce strategy long before a single robot is specified.
Built into a facility from the earliest design phases, material handling automation lets manufacturers hand off repetitive or physically demanding logistics work to technology while people concentrate on oversight and decision-making. That shift does double duty: it helps attract talent via modernized facilities, and it frees organizations to choose where to build based on strategic fit rather than local labor availability, lowering both cost and risk along the way. None of it works, though, without a human-centered approach that weaves robotics, architecture, manufacturing processes, operational technology and enterprise systems into one unified plan from the earliest project stages.
The automation maturity curve
Few facilities are all-in or all-out. Most sit somewhere on a maturity curve that runs from today's conventional manufacturing model to a fully autonomous concept that still exists mostly in theory. In a conventional plant, people drive logistics and machine tending by hand. Material transfers, sampling and cleaning stay manual even where isolated pockets of automation already exist. A mature, highly automated facility looks different: individual systems still operate independently, but they answer to a larger network of integrated intelligence that makes the whole operation more productive and efficient.
As new tools and innovations reach the market, that internal network keeps absorbing more processes and workflows. How well it does that depends heavily on the design and planning locked in at project initiation. Thinking of automation as a spectrum rather than a switch matters here. It lets manufacturers build a facility that can take on some automation now and more later, without tearing the building apart to do it.
Pharma has historically adopted robotics more cautiously than sectors like automotive or consumer goods, largely because of sterility demands, but that's changing quickly as the technology matures. When enough of these systems work in concert, the result is sometimes called a "lights-out" manufacturing facility: one that operates without needing constant human supervision.
A shift inside a lights-out manufacturing facility
Picture a shift on the floor of a next-generation fill-finish facility. Raw materials and consumables move into inventory without a forklift in sight, guided instead by autonomous mobile robots (AMRs), while automated depalletizing systems get "ready to use" (RTU) product tubs staged for the line. Once production starts, robotic systems take over component preparation and machine tending, automated sampling tools pull in-process samples for testing, and inspection platforms flag anomalies as they happen. Overnight, UV-enabled cleaning robots sanitize the space, and by morning the facility has reset itself for the next run, freeing operators to focus on the oversight, deviations and quality calls that require human judgment.
No single robot or AI model makes any of this happen. It's the coordination of hundreds of autonomous decisions running at once across the facility, built from technology that largely already exists: AMRs that move materials and finished product, robotics for palletizing and component handling, UV cleaning robots, and cobots capable of working alongside people without heavy guarding.
When off-the-shelf isn't enough: the case for a design partner
The most valuable opportunities tend to surface exactly where commercial technology runs out and a facility's specific needs keep going. Manufacturers chasing new modalities or novel production strategies routinely hit problems with no off-the-shelf fix, which is where an experienced solution partner, like Jacobs, can do more than engineer and design. Acting as co-creators alongside clients and technology vendors, our material handling automation design teams find the gaps in what's currently available and build facility-specific solutions to close them, including purpose-built component preparation systems, new approaches to material transfer, robotics strategies for demanding aseptic environments, or workflows that simply don't exist commercially yet.
That kind of collaboration lets manufacturers move forward on innovation at a pace they're comfortable with, without losing regulatory compliance or long-term flexibility.
Building around automation, not bolting it on
Material handling automation starts by mapping how materials, products, equipment, robots and people will interact across the full manufacturing lifecycle. AMR routes, the points where automated and manual work meet, charging locations, automated storage systems and maintenance access all need to be built into the concept design, not added after the fact. Even details like corridor widths, airlock and HVAC classification strategies, room layouts and how people move through the space end up shaping how well the automation performs.
It's worth clearing up a common misconception here: lights-out doesn't mean dark and empty. People remain essential to these operations, providing the oversight and judgment that technology still can't replicate on its own. Understanding exactly where human-robot collaboration adds the most value is itself a design input. The payoff goes beyond raw efficiency, too. Automating material handling strips out the low-value, repetitive work that skilled staff could come to resent, freeing them for tasks that move the needle on quality and output. Safety improves as well, since autonomous systems with sensors and collision-avoidance can take on the ergonomically risky material handling tasks that used to fall to people. Perhaps most importantly, this approach lets manufacturers stop treating automation as scattered "islands" and start planning automation, architecture, logistics and production systems together, so the facility runs as one integrated ecosystem that can adapt as the industry evolves.
What's still unresolved
None of this is as simple as buying the right robot. Cleanroom-qualified robotics are still an emerging market, and cross-contamination and segregation rules often eat up more space than a conventional layout provides. Autonomous quality assurance workflows, regulatory frameworks built for autonomous systems, and genuine interoperability between different vendors' platforms are all still maturing, as is the industry's collective sense of where human judgment should sit relative to autonomous decision-making.
Cost and ROI data on pharmaceutical automation solutions remain limited, which continues to complicate capital expenditure decisions; however, one thing is certain: planning ahead is still the smarter bet. Facilities built with automation in mind from day one can add new capabilities as they mature. Facilities that wait, on the other hand, could find that retrofitting costs more — in both dollars and downtime — than planning ahead would have.
The digital backbone: connecting IT and OT
None of this works without connectivity. Robotics may be the visible face of automated material handling systems, but the real foundation is the infrastructure that enables coordination across the digital ecosystem.
That means tightly integrated IT and OT environments, where Manufacturing Execution Systems (MES), fleet management software, building management systems, process control platforms, asset tracking, warehouse management systems and enterprise applications all function as one connected architecture rather than a patchwork of separate tools.
Reliable wireless connectivity becomes mission-critical in this environment, since AMRs need continuous communication as they move across large footprints spanning production spaces, warehouses, gowning areas, labs and support areas. Wireless infrastructure must be designed with future fleet growth and additional connected devices in mind, not just today's requirements.
On top of that, these lights-out ecosystems depend on digital identities, real-time location tracking, chain-of-custody records and tight integration with production schedules so intelligent systems can navigate complex process flows accurately in real time.
Security and intelligence, built in from day one
A more connected facility means more operational assets exposed across digital networks, requiring a robust security response. Cybersecurity has to be designed into the facility architecture from the start, with network segmentation, secure communications protocols, identity management and governance frameworks as foundational pieces, not afterthoughts.
Looking ahead, pharma facilities will lean more heavily on AI and advanced analytics, both to run better and to manage the construction programs that build them. That matters more as digital twins and predictive analytics move out of pilot projects and into enterprise-wide use, supporting predictive maintenance, intelligent scheduling, quality monitoring and adaptive process optimization that catch issues earlier and support better decisions. Over time, AI-enabled systems may move from simply flagging problems to initiating corrective action through connected control systems and enterprise platforms.
All of which points to a broader truth: material handling automation isn't just a technology purchase — it's a design philosophy. Getting it right means integrating design elements and people into one operating model that can keep adapting across decades of technological change.
The bottom line
The pharma facilities of the future will be defined by how well technology and people work together, not by automation on its own. As demand for advanced therapies keeps accelerating, manufacturers face growing pressure to add capacity without letting quality slip. Automated material handling systems offer a way to do both, pairing robotics, intelligent facility design and connected digital ecosystems into manufacturing environments that are more efficient and easier to adapt over time.
But this isn't a future problem. Corridor widths, wireless infrastructure, control architecture and cleanroom layouts made today can lock in an operating model for decades. A facility designed with automation in mind from the start can pick up new capabilities as they mature, instead of rebuilding around them later. The organizations getting the most out of this shift treat it as a comprehensive design philosophy that aligns facilities, operations and workforce strategy around a shared goal, rather than a pile of individual technologies.
Because in the end, the point isn't automation for its own sake. It's better patient outcomes, delivered through comprehensive, future-ready automation that strengthens manufacturing resilience and speeds up the delivery of life-changing medicines.